Revised SPC: Opdivo (nivolumab) 10 mg/mL concentrate for solution for infusion

SPC revised with licence extension to include use in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Source:

electronic Medicines compendium